Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD Inc (TXMD) is an innovative pharmaceutical company focused on advancing women's health through specialized therapies and strategic licensing partnerships. This page serves as the definitive source for all official company announcements, regulatory updates, and market developments.
Investors and industry professionals will find timely updates on TXMD's prescription products including IMVEXXY, BIJUVA, and ANNOVERA, along with financial disclosures and partnership agreements. Our curated news feed covers essential developments including FDA milestones, licensing expansions with commercial partners like Mayne Pharma, and clinical research advancements.
Key updates include earnings reports, product pipeline progress, intellectual property developments, and strategic initiatives in the women's healthcare sector. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to TherapeuticsMD's latest press releases and objective news coverage. Check regularly for updates on pharmaceutical royalties, regulatory decisions, and market positioning within the competitive women's health landscape.
TherapeuticsMD (NASDAQ: TXMD) reported its Q1 2025 financial results, showing a reduced net loss from continuing operations of $(636) thousand ($(0.06) per share), compared to $(809) thousand ($(0.07) per share) in Q1 2024. License revenues increased 25.8% to $393 thousand, primarily from the Mayne License Agreement, up from $313 thousand in Q1 2024. Operating expenses decreased 13.1% to $1,264 thousand due to improved efficiencies as a royalty-based business.
The company maintains $5.7 million in cash and cash equivalents as of March 31, 2025. TherapeuticsMD is actively evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales, though no specific timeline or guaranteed outcome has been established.
TherapeuticsMD (NASDAQ: TXMD) has reported its full year 2024 financial results, showing improved performance with a reduced net loss from continuing operations of $(2.3) million, or $(0.20) per share, compared to $(7.7) million, or $(0.74) per share in 2023.
The company's license revenue, primarily from the Mayne License Agreement, increased by 35.3% to $1.8 million in 2024, up from $1.3 million in 2023. Operating expenses decreased by 33.6% to $6.5 million from $9.8 million in 2023, reflecting the company's transition from a commercial to a royalty-based business model.
As of December 31, 2024, TXMD maintained $5.1 million in cash and cash equivalents. The company is currently evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q3 2024 financial results, showing a reduced net loss of $(567) thousand ($(0.05) per share) compared to $(1.4) million ($(0.13) per share) in Q3 2023. License revenue, mainly from the Mayne License Agreement, increased to $547 thousand from $(53) thousand in Q3 2023. Operating expenses decreased by 18.3% to $1.4 million. The company ended the quarter with $5.0 million in cash and cash equivalents. TherapeuticsMD is currently evaluating strategic alternatives, including potential mergers, acquisitions, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q2 2024 financial results. The company, which owns pharmaceutical royalty rights, saw a net loss from continuing operations of $1.05 million ($0.09 per share), an improvement from the $2.4 million loss in Q2 2023. License revenue decreased by 46.5% to $234,000, primarily due to changes in sales of licensed products. Total operating expenses decreased by 8.1% to $2.7 million, reflecting cost optimization efforts. The company's cash and cash equivalents stood at $5.2 million as of June 30, 2024. TherapeuticsMD is currently evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales.
TherapeuticsMD, Inc. reported its First Quarter 2024 Financial Results, showing a net loss from continuing operations of $(0.8) million, or $(0.07) per share, compared to $(2.3) million in 2023. The company generated approximately $1.2 million in gross license royalties under the Mayne License Agreement, with total operating expenses decreasing by 52.8% to $1.5 million. Additionally, the company is exploring various strategic alternatives without a set timetable for completion.
TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for 2022, highlighting a significant turnaround with a net income of $1.1 million ($0.12 per share), compared to a net loss of $79.3 million in 2021. This improvement is attributed to increased licensing revenues from its exclusive agreement with Mayne Pharma, which amounted to $70 million in 2022, a steep rise from just $2.6 million the previous year. Operating expenses decreased to $67.4 million from $80.7 million in 2021, reflecting cost-cutting measures following the transaction with Mayne Pharma. However, cash reserves fell to $38.1 million from $64.9 million year-over-year. The company eliminated debt totaling $188.3 million after the Mayne Pharma deal, while also redeeming preferred stock. Future outlook remains focused on streamlining operations and potentially creating value through additional strategic initiatives.
FAQ
What is the current stock price of Therapeuticsmd (TXMD)?
What is the market cap of Therapeuticsmd (TXMD)?
